4-Butylresorcinol |CAS 18979-61-8|DC Chemicals

Cas No.:	18979-61-8
Chemical Name:	4-Butylresorcinol
Synonyms:	4-Butylbenzene-1,3-diol;4-N-BUTYLRESORCINOL;2,4-DIHYDROXY-N-BUTYL BENZENE;2,4-DIHYDROXY-N-BUTYL BENZEN;2,4-Dihydroxy-n-bytyl benzen;4-Butylresorcinol;1-butyl-2,4-dihydroxybenzene;4-Butylresorcin;4-butyl-resorcinol;Butylresorcinol;N-butylresorcinol;Resorcinol,4-butyl;4-Butyl-1,3-benzenediol;N-BUTYLRESEOCINOL;4-phenylbutane-1,3-diol;1,3-Benzenediol,4-butyl-;Resorcinol, 4-butyl-;Rucinol;2IK4UQ3ZGA;1,3-Benzenediol, 4-butyl-;Kopcinol;4-(2,4-dihydroxyphenyl)butane;n-butyl resorcinol;Rucinol (TN);D;4-BUTYLRESORCINOL,98+%
SMILES:	O([H])C1C([H])=C(C([H])=C([H])C=1C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])O[H]
Formula:	C₁₀H₁₄O₂
M.Wt:	166.2170
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

In Vitro It shows that 4-Butylresorcinol (4-n-butylresorcinol) significantly inhibits melanin synthesis in a concentration-dependent manner. In addition, it is also found to inhibit the activity of tyrosinase, the rate-limiting melanogenic enzyme. 4-Butylresorcinol does not induce ERK, Akt activation, or MITF degradation, and has no effect on cAMP response element binding protein (CREB) phosphorylation, which stimulates MITF expression. 4-Butylresorcinol strongly reduces tyrosinase activity in a cell-free system. Moreover, 4-Butylresorcinol shows an additive effect in combination with hinokitiol, which reduces MITF expression.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.